Maintaining Buy Rating on Liquidia Technologies Amidst FDA Delay, Optimistic on Yutrepia's Market Potential
Liquidia Analyst Ratings
Bullish Outlook for Liquidia Technologies With Buy Rating Amid Anticipated Patent Clarity and Market Growth Opportunities
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)
Buy Rating for Liquidia Technologies: Innovation and Market Potential Drive Strong Investment Case
Liquidia Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)
Buy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies' Yutrepia
Liquidia Analyst Ratings
Liquidia Analyst Ratings
Liquidia Technologies Faces Sell Rating Amid Legal Struggles and Market Competition
Buy Rating Affirmed for Liquidia Technologies With Doubling Price Target on Yutrepia's Promising Prospects
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Legend Biotech (LEGN)
Liquidia Analyst Ratings
Buy Rating Affirmed for Liquidia Technologies Amid Favorable Legal Rulings and Yutrepia's Market Potential
Liquidia Analyst Ratings
Buy Rating Affirmed for Liquidia Technologies Amidst Strong Market Growth and Favorable Regulatory Outlook
Maintaining Buy Rating on Liquidia Technologies Amid FDA Delay: A Procedural Hiccup, Not a Setback
Buy Rating Upheld for Liquidia Technologies Amid Strong Market Prospects for YUTREPIA
Buy Rating Affirmed for Liquidia Technologies Post-Court Win and Strong Financial Position
No Data